CytoMed Therapeutics Stock Forecast - Simple Regression
| GDTC Stock | 1.00 0.05 5.26% |
The Simple Regression forecasted value of CytoMed Therapeutics Limited on the next trading day is expected to be 1.01 with a mean absolute deviation of 0.08 and the sum of the absolute errors of 4.65. CytoMed Stock Forecast is based on your current time horizon. Investors can use this forecasting interface to forecast CytoMed Therapeutics stock prices and determine the direction of CytoMed Therapeutics Limited's future trends based on various well-known forecasting models. We recommend always using this module together with an analysis of CytoMed Therapeutics' historical fundamentals, such as revenue growth or operating cash flow patterns.
At the present time the rsi of CytoMed Therapeutics' share price is below 20 . This usually indicates that the stock is significantly oversold. The fundamental principle of the Relative Strength Index (RSI) is to quantify the velocity at which market participants are driving the price of a financial instrument upwards or downwards. Momentum 0
Sell Peaked
Oversold | Overbought |
Wall Street Target Price 5 | EPS Estimate Current Quarter (0.04) | Quarterly Revenue Growth 1.01 |
Using CytoMed Therapeutics hype-based prediction, you can estimate the value of CytoMed Therapeutics Limited from the perspective of CytoMed Therapeutics response to recently generated media hype and the effects of current headlines on its competitors.
The Simple Regression forecasted value of CytoMed Therapeutics Limited on the next trading day is expected to be 1.01 with a mean absolute deviation of 0.08 and the sum of the absolute errors of 4.65. CytoMed Therapeutics after-hype prediction price | USD 1.19 |
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
Check out Historical Fundamental Analysis of CytoMed Therapeutics to cross-verify your projections. CytoMed Therapeutics Additional Predictive Modules
Most predictive techniques to examine CytoMed price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for CytoMed using various technical indicators. When you analyze CytoMed charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
CytoMed Therapeutics Simple Regression Price Forecast For the 25th of January
Given 90 days horizon, the Simple Regression forecasted value of CytoMed Therapeutics Limited on the next trading day is expected to be 1.01 with a mean absolute deviation of 0.08, mean absolute percentage error of 0.01, and the sum of the absolute errors of 4.65.Please note that although there have been many attempts to predict CytoMed Stock prices using its time series forecasting, we generally do not recommend using it to place bets in the real market. The most commonly used models for forecasting predictions are the autoregressive models, which specify that CytoMed Therapeutics' next future price depends linearly on its previous prices and some stochastic term (i.e., imperfectly predictable multiplier).
CytoMed Therapeutics Stock Forecast Pattern
| Backtest CytoMed Therapeutics | CytoMed Therapeutics Price Prediction | Buy or Sell Advice |
CytoMed Therapeutics Forecasted Value
In the context of forecasting CytoMed Therapeutics' Stock value on the next trading day, we examine the predictive performance of the model to find good statistically significant boundaries of downside and upside scenarios. CytoMed Therapeutics' downside and upside margins for the forecasting period are 0.01 and 6.50, respectively. We have considered CytoMed Therapeutics' daily market price to evaluate the above model's predictive performance. Remember, however, there is no scientific proof or empirical evidence that traditional linear or nonlinear forecasting models outperform artificial intelligence and frequency domain models to provide accurate forecasts consistently.
Model Predictive Factors
The below table displays some essential indicators generated by the model showing the Simple Regression forecasting method's relative quality and the estimations of the prediction error of CytoMed Therapeutics stock data series using in forecasting. Note that when a statistical model is used to represent CytoMed Therapeutics stock, the representation will rarely be exact; so some information will be lost using the model to explain the process. AIC estimates the relative amount of information lost by a given model: the less information a model loses, the higher its quality.| AIC | Akaike Information Criteria | 115.1655 |
| Bias | Arithmetic mean of the errors | None |
| MAD | Mean absolute deviation | 0.075 |
| MAPE | Mean absolute percentage error | 0.0505 |
| SAE | Sum of the absolute errors | 4.6526 |
Predictive Modules for CytoMed Therapeutics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as CytoMed Therapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of CytoMed Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
CytoMed Therapeutics After-Hype Price Prediction Density Analysis
As far as predicting the price of CytoMed Therapeutics at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in CytoMed Therapeutics or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Stock prices, such as prices of CytoMed Therapeutics, with the unreliable approximations that try to describe financial returns.
Next price density |
| Expected price to next headline |
CytoMed Therapeutics Estimiated After-Hype Price Volatility
In the context of predicting CytoMed Therapeutics' stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on CytoMed Therapeutics' historical news coverage. CytoMed Therapeutics' after-hype downside and upside margins for the prediction period are 0.06 and 6.68, respectively. We have considered CytoMed Therapeutics' daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models outperform traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
CytoMed Therapeutics is dangerous at this time. Analysis and calculation of next after-hype price of CytoMed Therapeutics is based on 3 months time horizon.
CytoMed Therapeutics Stock Price Prediction Analysis
Have you ever been surprised when a price of a Company such as CytoMed Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading CytoMed Therapeutics backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with CytoMed Therapeutics, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
1.28 | 5.49 | 0.19 | 0.20 | 20 Events / Month | 5 Events / Month | In about 20 days |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | ||
1.00 | 1.19 | 19.00 |
|
CytoMed Therapeutics Hype Timeline
CytoMed Therapeutics is currently traded for 1.00. The entity has historical hype elasticity of 0.19, and average elasticity to hype of competition of -0.2. CytoMed is anticipated to increase in value after the next headline, with the price projected to jump to 1.19 or above. The average volatility of media hype impact on the company the price is over 100%. The price growth on the next news is projected to be 19.0%, whereas the daily expected return is currently at -1.28%. The volatility of related hype on CytoMed Therapeutics is about 3496.82%, with the expected price after the next announcement by competition of 0.80. CytoMed Therapeutics Limited currently holds 339.2 K in liabilities. Note, when we think about CytoMed Therapeutics' use of debt, we should always consider it together with its cash and equity.Given the investment horizon of 90 days the next anticipated press release will be in about 20 days. Check out Historical Fundamental Analysis of CytoMed Therapeutics to cross-verify your projections.CytoMed Therapeutics Related Hype Analysis
Having access to credible news sources related to CytoMed Therapeutics' direct competition is more important than ever and may enhance your ability to predict CytoMed Therapeutics' future price movements. Getting to know how CytoMed Therapeutics' peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how CytoMed Therapeutics may potentially react to the hype associated with one of its peers.
| HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
| ENLV | Enlivex Therapeutics | 0.15 | 2 per month | 3.98 | 0.01 | 8.57 | (7.53) | 24.21 | |
| MTVA | MetaVia | (0.87) | 9 per month | 0.00 | (0.14) | 11.60 | (20.10) | 79.95 | |
| NCNA | NuCana PLC | 0.15 | 2 per month | 0.00 | (0.14) | 6.97 | (7.87) | 16.72 | |
| NRSN | Neurosense Therapeutics | (0.03) | 10 per month | 0.00 | (0.05) | 12.82 | (7.48) | 34.62 | |
| LSTA | Lisata Therapeutics | 0.15 | 10 per month | 2.85 | 0.10 | 5.58 | (5.26) | 85.83 | |
| CLGN | Collplant Biotechnologies | 0.18 | 8 per month | 0.00 | (0.07) | 8.51 | (7.84) | 20.81 | |
| NRXS | Neuraxis | 0.15 | 11 per month | 4.61 | 0.09 | 7.88 | (8.64) | 38.80 | |
| PASG | Passage Bio | 0.15 | 14 per month | 6.09 | 0.10 | 14.59 | (9.39) | 58.13 | |
| XCUR | Exicure | (1.02) | 9 per month | 7.40 | 0.08 | 21.22 | (9.76) | 63.80 | |
| SONN | Sonnet Biotherapeutics Holdings | (0.58) | 8 per month | 0.00 | (0.02) | 19.48 | (18.21) | 69.59 |
Other Forecasting Options for CytoMed Therapeutics
For every potential investor in CytoMed, whether a beginner or expert, CytoMed Therapeutics' price movement is the inherent factor that sparks whether it is viable to invest in it or hold it better. CytoMed Stock price charts are filled with many 'noises.' These noises can hugely alter the decision one can make regarding investing in CytoMed. Basic forecasting techniques help filter out the noise by identifying CytoMed Therapeutics' price trends.CytoMed Therapeutics Related Equities
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with CytoMed Therapeutics stock to make a market-neutral strategy. Peer analysis of CytoMed Therapeutics could also be used in its relative valuation, which is a method of valuing CytoMed Therapeutics by comparing valuation metrics with similar companies.
| Risk & Return | Correlation |
CytoMed Therapeutics Market Strength Events
Market strength indicators help investors to evaluate how CytoMed Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading CytoMed Therapeutics shares will generate the highest return on investment. By undertsting and applying CytoMed Therapeutics stock market strength indicators, traders can identify CytoMed Therapeutics Limited entry and exit signals to maximize returns.
| Accumulation Distribution | 610.38 | |||
| Daily Balance Of Power | 0.8333 | |||
| Rate Of Daily Change | 1.05 | |||
| Day Median Price | 0.97 | |||
| Day Typical Price | 0.98 | |||
| Price Action Indicator | 0.055 | |||
| Period Momentum Indicator | 0.05 |
CytoMed Therapeutics Risk Indicators
The analysis of CytoMed Therapeutics' basic risk indicators is one of the essential steps in accurately forecasting its future price. The process involves identifying the amount of risk involved in CytoMed Therapeutics' investment and either accepting that risk or mitigating it. Along with some essential techniques for forecasting cytomed stock prices, we also provide a set of basic risk indicators that can assist in the individual investment decision or help in hedging the risk of your existing portfolios.
| Mean Deviation | 3.8 | |||
| Standard Deviation | 5.44 | |||
| Variance | 29.54 |
Please note, the risk measures we provide can be used independently or collectively to perform a risk assessment. When comparing two potential investments, we recommend comparing similar equities with homogenous growth potential and valuation from related markets to determine which investment holds the most risk.
Story Coverage note for CytoMed Therapeutics
The number of cover stories for CytoMed Therapeutics depends on current market conditions and CytoMed Therapeutics' risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme that CytoMed Therapeutics is classified under. However, while its typical story may have numerous social followers, the rapid visibility can also attract short-sellers, who usually are skeptical about CytoMed Therapeutics' long-term prospects. So, having above-average coverage will typically attract above-average short interest, leading to significant price volatility.
Contributor Headline
Latest Perspective From Macroaxis
CytoMed Therapeutics Short Properties
CytoMed Therapeutics' future price predictability will typically decrease when CytoMed Therapeutics' long traders begin to feel the short-sellers pressure to drive the price lower. The predictive aspect of CytoMed Therapeutics Limited often depends not only on the future outlook of the potential CytoMed Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. CytoMed Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 11.5 M | |
| Cash And Short Term Investments | 3.6 M |
Check out Historical Fundamental Analysis of CytoMed Therapeutics to cross-verify your projections. You can also try the Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of CytoMed Therapeutics. If investors know CytoMed will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about CytoMed Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.25) | Revenue Per Share | Quarterly Revenue Growth 1.01 | Return On Assets | Return On Equity |
The market value of CytoMed Therapeutics is measured differently than its book value, which is the value of CytoMed that is recorded on the company's balance sheet. Investors also form their own opinion of CytoMed Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is CytoMed Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because CytoMed Therapeutics' market value can be influenced by many factors that don't directly affect CytoMed Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between CytoMed Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if CytoMed Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, CytoMed Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.